X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (261) 261
oncology (178) 178
female (144) 144
male (131) 131
middle aged (106) 106
adult (105) 105
aged (101) 101
pharmacokinetics (97) 97
index medicus (82) 82
neoplasms - drug therapy (81) 81
animals (76) 76
pharmacology & pharmacy (73) 73
antineoplastic agents, phytogenic - pharmacokinetics (72) 72
antineoplastic agents - pharmacokinetics (70) 70
cancer (61) 61
camptothecin - analogs & derivatives (58) 58
mice (50) 50
area under curve (49) 49
camptothecin - pharmacokinetics (47) 47
paclitaxel (46) 46
phase-i (43) 43
paclitaxel - pharmacokinetics (41) 41
antineoplastic agents - administration & dosage (40) 40
article (40) 40
antineoplastic agents, phytogenic - administration & dosage (37) 37
dose-response relationship, drug (35) 35
pharmacogenetics (35) 35
metabolism (34) 34
neoplasms - metabolism (34) 34
p-glycoprotein (33) 33
docetaxel (31) 31
irinotecan (31) 31
administration, oral (30) 30
infusions, intravenous (30) 30
human plasma (29) 29
chemistry, analytical (28) 28
paclitaxel - administration & dosage (28) 28
biochemical research methods (27) 27
chemotherapy (27) 27
cremophor el (27) 27
cell lung-cancer (26) 26
clinical pharmacokinetics (26) 26
drug administration schedule (26) 26
genotype (26) 26
camptothecin - administration & dosage (25) 25
cpt-11 (24) 24
expression (24) 24
research (24) 24
reproducibility of results (23) 23
antineoplastic agents - therapeutic use (22) 22
antineoplastic agents, phytogenic - therapeutic use (22) 22
beer (22) 22
biochemistry (22) 22
chemistry (22) 22
compositions or test papers therefor (22) 22
condition-responsive control in microbiological orenzymological processes (22) 22
enzymology (22) 22
measuring or testing processes involving enzymes, nucleicacids or microorganisms (22) 22
metallurgy (22) 22
microbiology (22) 22
mutation or genetic engineering (22) 22
processes of preparing such compositions (22) 22
spirits (22) 22
vinegar (22) 22
wine (22) 22
antineoplastic agents - pharmacology (21) 21
cisplatin (21) 21
disposition (21) 21
glycerol - analogs & derivatives (21) 21
metabolic clearance rate (21) 21
time factors (21) 21
antineoplastic agents, phytogenic - blood (19) 19
cisplatin - administration & dosage (19) 19
drug interactions (19) 19
mice, knockout (19) 19
polymorphisms (19) 19
sn-38 (19) 19
antineoplastic agents - blood (18) 18
antineoplastic agents, phytogenic - adverse effects (18) 18
body surface area (18) 18
chromatography, high pressure liquid (18) 18
enzyme inhibitors - pharmacokinetics (18) 18
pharmacodynamics (18) 18
sensitivity and specificity (18) 18
taxol (18) 18
aged, 80 and over (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
binding (17) 17
cytochrome p-450 cyp3a (17) 17
imatinib mesylate (17) 17
in-vitro (17) 17
metabolites (17) 17
neutropenia - chemically induced (17) 17
phenotype (17) 17
antineoplastic agents - metabolism (16) 16
breast-cancer (16) 16
cancer-patients (16) 16
chromatography, high pressure liquid - methods (16) 16
multidrug-resistance (16) 16
neoplasms - genetics (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 03/2015, Volume 21, Issue 6, pp. 1237 - 1239
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 35, pp. 5972 - 5978
Purpose Methotrexate plasma concentration is related to its clinical effects. Our aim was to identify the genetic basis of interindividual variability in... 
RHEUMATOID-ARTHRITIS | DRUG-THERAPY | INFLAMMATORY-BOWEL-DISEASE | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | ACUTE LYMPHOCYTIC-LEUKEMIA | HIGH-DOSE METHOTREXATE | SLCO1B1 POLYMORPHISM | OATP-C | GENOME-WIDE ASSOCIATION | SINGLE NUCLEOTIDE POLYMORPHISMS | Prospective Studies | Antimetabolites, Antineoplastic - pharmacokinetics | Humans | Methotrexate - pharmacokinetics | Child, Preschool | Infant | Male | Organic Anion Transporters - metabolism | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism | Organic Anion Transporters - genetics | Antimetabolites, Antineoplastic - blood | Germ-Line Mutation | Female | Child | Genetic Predisposition to Disease | Genome-Wide Association Study | Risk Assessment | Risk Factors | Linear Models | Logistic Models | Treatment Outcome | Methotrexate - blood | Linkage Disequilibrium | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Methotrexate - adverse effects | Phenotype | Gastrointestinal Diseases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Antimetabolites, Antineoplastic - adverse effects | Polymorphism, Single Nucleotide | Solute Carrier Organic Anion Transporter Family Member 1b1 | Gastrointestinal Diseases - chemically induced | Index Medicus | Original Reports | Pedi2
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2004, Volume 22, Issue 12, pp. 2489 - 2503
Journal Article
Molecular Pharmacology, ISSN 0026-895X, 10/2005, Volume 68, Issue 4, pp. 917 - 932
Journal Article
Current Clinical Pharmacology, ISSN 1574-8847, 2010, Volume 5, Issue 3, pp. 209 - 217
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2009, Volume 15, Issue 19, pp. 6062 - 6069
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2013, Volume 110, Issue 27, pp. 11199 - 11204
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2017, Volume 23, Issue 24, pp. 7454 - 7466
Purpose: AZD1775, a first-in-class, small-molecule inhibitor of the Wee1 tyrosine kinase, is under evaluation as a potential chemo-and radiosensitizer for... 
TRANSPORTING POLYPEPTIDE 1A2 | DNA-DAMAGING AGENTS | WEE1 KINASE | GENETIC POLYMORPHISMS | PERMEABILITY | ONCOLOGY | DRUG DISPOSITION | METHOTREXATE | P53-DEFICIENT TUMOR-CELLS | CANCER | P-GLYCOPROTEIN | Humans | Middle Aged | Cell Cycle Proteins - antagonists & inhibitors | Organic Anion Transporters - genetics | Protein-Tyrosine Kinases - genetics | Glioblastoma - genetics | Madin Darby Canine Kidney Cells | Aged, 80 and over | Cell Cycle Proteins - genetics | Adult | ATP Binding Cassette Transporter, Subfamily B - genetics | Biological Transport - genetics | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - genetics | Nuclear Proteins - genetics | Pyrazoles - pharmacokinetics | Pyrazoles - adverse effects | Tumor Microenvironment - drug effects | Pyrimidines - administration & dosage | ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics | Blood-Brain Barrier - drug effects | Pyrazoles - administration & dosage | Animals | Glioblastoma - pathology | Nuclear Proteins - antagonists & inhibitors | Dogs | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Glioblastoma - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Efflux | Brain | Brain tumors | Brain cancer | Glioblastoma | Pharmacology | Permeability | Metabolism | pH effects | Patients | Blood | Substrates | Penetration | Blood-brain barrier | Experimental design | Drug metabolism | Mathematical models | Kinetics | Pharmacokinetics | Protein-tyrosine kinase | Transporter | Cancer | Integrity
Journal Article
Journal Article